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Abstract
Background: Results from the recent CROSS trial showed that neoadjuvant chemoradiotherapy (nCRT) significantly increased
survival as compared to surgery alone in patients with potentially curable esophageal cancer. Furthermore, in the nCRT arm 49%
of patients with a squamous cell carcinoma (SCC) and 23% of patients with an adenocarcinoma (AC) had a pathologically
complete response in the resection specimen. These results provide a rationale to reconsider and study the timing and necessity
of esophagectomy in (all) patients after application of the CROSS regimen.
Objective: We propose a “surgery as needed” approach after completion of nCRT. In this approach, patients will undergo active
surveillance after completion of nCRT. Surgical resection would be offered only to those patients in whom residual disease or a
locoregional recurrence is highly suspected or proven. However, before a surgery as needed approach in oesophageal cancer
patients (SANO) can be tested in a randomized controlled trial, we aim to determine the accuracy of detecting the presence or
absence of residual disease after nCRT (preSANO trial).
Methods: This study is set up as a prospective, single arm, multicenter, diagnostic trial. Operable patients with potentially
curable SCC or AC of the esophagus or esophagogastric junction will be included. Approximately 4-6 weeks after completion
of nCRT all included patients will undergo a first clinical response evaluation (CRE-I) including endoscopy with (random)
conventional mucosal biopsies of the primary tumor site and of any other suspected lesions in the esophagus and radial
endo-ultrasonography (EUS) for measurement of tumor thickness and area. Patients in whom no locoregional or disseminated
disease can be proven by cytohistology will be offered a postponed surgical resection 6-8 weeks after CRE-I (ie, approximately
12-14 weeks after completion of nCRT). In the week preceding the postponed surgical resection, a second clinical response
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evaluation (CRE-II) will be planned that will include a whole body PET-CT, followed again by endoscopy with (random)
conventional mucosal biopsies of the primary tumor site and any other suspected lesions in the esophagus, radial EUS for
measurement of tumor thickness and area, and linear EUS plus fine needle aspiration of PET-positive lesions and/or suspected
lymph nodes. The main study parameter is the correlation between the clinical response assessment during CRE-I and CRE-II
and the final pathological response in the resection specimen.
Results: The first patient was enrolled on July 23, 2013, and results are expected in January 2016.
Conclusions: If this preSANO trial shows that the presence or absence of residual tumor can be predicted reliably 6 or 12 weeks
after completion of nCRT, a randomized trial comparing nCRT plus standard surgery versus chemoradiotherapy plus “surgery
as needed” will be conducted (SANO trial).
Trial Registration: Netherlands Trial Register: NTR4834; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4834
(archived by Webcite at http://www.webcitation.org/6Ze7mn67B).
(JMIR Res Protoc 2015;4(2):e79)   doi:10.2196/resprot.4320
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Introduction
Background
Cancer of the esophagus remains a highly lethal malignancy,
as reflected by an average overall 5-year survival of 17% [1].
In the Netherlands, the incidence of esophageal cancer resembles
the growing trend in Western countries, with an estimated
incidence of 15/100,000 for men and 6/100,000 for women [2]
and more than 2,500 new cases being diagnosed nationally each
year.
At present, surgical resection is still considered the cornerstone
of curative treatment for patients eligible with stage
cT1b-4aN0-3M0 disease. The reported 5-year survival rate for
patients who undergo an esophagectomy ranges from 20% to
50%, but rarely exceeds 35% [3-7]. Esophagectomy is associated
with postoperative mortality rates of 1% to 5% in high-volume
centers, severe postoperative morbidity, and a substantial impact
on the quality of life [8-13]. In order to improve the radicality
of surgical resection and the long-term survival after surgical
resection, many trials have been performed to study the effect
of neoadjuvant chemo and/or radiation therapy [14-17]. One of
the largest trials is the recently published chemoradiotherapy
for oesophageal cancer followed by surgery study (CROSS
trial). This randomized trial compared neoadjuvant
chemoradiotherapy (nCRT) plus surgery to surgery alone [18].
During a 5-year period, 366 patients from 5 academic and 2
nonacademic high-volume teaching hospitals in the Netherlands
were included in the CROSS trial. Results showed that the
addition of nCRT (carboplatin AUC2, paclitaxel 50 mg/m2, and
41.4 Gy of concurrent radiotherapy) to surgery significantly
increases long-term survival as compared to surgery alone.
Median overall survival of patients who received nCRT plus
surgery was 49 months, compared to 24 months for those who
received surgery alone, and the 3-year overall survival was
superior in the nCRT arm (hazard ratio (HR) = 0.66; 95%
confidence interval (CI) 0.50-0.87; P=.003). Therefore, nCRT
plus surgery is now considered the therapy of choice in the
Netherlands and several other countries for potentially curable
esophageal cancer (cT2-3N0-3M0 and cT1N1-3M0, according
to the UICC TNM classification [19]). In subsequent analyses
of secondary endpoints of the CROSS trial an interesting
observation was made. In the nCRT arm, 49% of patients with
a squamous cell carcinoma (SCC) and 23% of patients with an
adenocarcinoma (AC) had a pathologically complete response
(pCR) in the resection specimen (ie, no viable tumor cells were
found, neither at the site of the primary tumor nor in the resected
regional lymph nodes, as determined by conventional
histological examination) [18]. Therefore, these results provide
a rationale to reconsider and study the timing and necessity of
standard esophagectomy in patients after application of the
CROSS regimen.
Objective
We propose a “surgery as needed” approach after completion
of nCRT for carcinoma of the esophagus. In this surgery as
needed approach, patients will undergo active surveillance after
completion of nCRT. Surgical resection would be offered only
to those patients in whom a locoregional recurrence is highly
suspected or proven, in the absence of any signs of distant
dissemination. Such an organ-preserving strategy would clearly
have great advantages. Postoperative mortality and severe
morbidity (grade ≥3 according to the Clavien-Dindo
classification [20]) after esophagectomy in the Netherlands is
5% and 60%, respectively. Thus, a nonsurgical treatment
strategy in patients with a clinically complete response after
nCRT, theoretically saves 5% mortality and 60% severe
morbidity in this patient group. Moreover, this approach might
improve quality of life and might lead to a reduction in health
care costs. However, this surgery as needed approach is only
favorable if long-term survival would be comparable to that of
the trimodality approach comprising nCRT followed by standard
surgery. Before a surgery as needed approach can be tested in
a randomized trial, we aim to determine the feasibility of
accurate detection of residual disease after chemoradiotherapy
through a surgery as needed in oesophageal cancer patients
study (preSANO trial).
The aim of this present prospective, multicenter, and diagnostic
preSANO trial is to determine the accuracy by which we can
detect the presence or absence of residual disease after nCRT.
The results of this trial will inform us about the percentage of
patients with a clinically complete response after nCRT and
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will help to estimate the number of patients needed for a
subsequent randomized controlled trial. The future so-called
“SANO trial” will randomize patients into 2 strategy groups:
(1) nCRT plus surgery, and (2) nCRT followed by an active
surveillance.
Methods
Study Design
The preSANO trial is a prospective, multicenter, diagnostic trial
including 120 patients, using a single arm. Five high-volume
centers in the Netherlands are currently participating in this
study: Erasmus Medical Center, Rotterdam; Academic Medical
Center, Amsterdam; University Medical Center, Utrecht;
Catharina Cancer Center, Eindhoven; and Atrium Medical
Center, Heerlen. The study has been approved by the medical
ethics committee (MEC) of the Erasmus Medical Center
(MEC2013-211) and has been registered in the Netherlands
Trial Register (NTR4834).
Study Population
We plan to include individuals from a population of operable
patients with potentially curable SCC or AC of the esophagus
or esophagogastric junction. All patients who are planned to
undergo nCRT according to the CROSS regimen [18] followed
by surgical resection are eligible to participate. Patients with
dementia or altered mental status prohibiting the understanding
and giving of informed consent will be excluded from
participation in this study. Patients will undergo conventional
pretreatment selection (including at least a “partial body”
F18-FDG positron emission tomography-computed tomography
(PET-CT) to assess the avidity of the primary tumor process;
Figure 1 and Table 1).
Table 1. Study algorithm.
Second clinical response evaluation
(CRE-II)
First clinical response evaluation
(CRE-I)
PretreatmentParameter
XXXHistory, physical examination
XXXPerformance status
XHematologya
XeGFR
XBiochemistryb
XXXEndoscopy + (random) biopsies
XXXRadial EUSc
XXLinear EUS (+FNA)d
XCT of neck, thorax, abdomen, and
pelvis
Xh“whole body”Xg“whole body”X “partial body”PET-CT
XPulmonary function tests
XBronchoscopye
XECG
BaselineToxicityf
aHematology: CBC, differential
bBiochemistry: serum protein, albumin, magnesium, electrolytes, serum creatinine, bilirubin, alkaline phosphatase, AST, and pregnancy test if indicated
at baseline only
cRadial EUS: with measurement of maximum tumor thickness and area
dLinear EUS: with FNA of any suspected lymph nodes
eBronchoscopy: when tumor is located above the carina and when there is suspicion for invasion of the tracheobronchial tree
fToxicity: to be evaluated after each cycle (incidence and grade according to CTC toxicity scale)
gPET-CT: during CRE-I, after EGD and EUS, only for clinically noncomplete responders to exclude disseminated disease
hPET-CT: during CRE-II, prior to EGD and EUS, for all patients (all were clinically complete responders during CRE-I) to guide EGD and EUS in
targeting suspected locoregional lesions and to exclude disseminated disease
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Figure 1. Study algorithm. 1. During the pretreatment workup, it suffices when a “partial body” F18-FDG PET-CT of the esophagus will be performed
(to test for avidity of the primary lesion); if it is preferred to make a “whole-body” PET-CT not only after, but also before the neoadjuvant
chemoradiotherapy in order to detect distant metastases at an earlier stage, the indication for performing an external US with FNA of the neck can be
limited to those patients who have a suspected lymph node on the PET-CT [23]. In the period after neoadjuvant therapy, 1 whole-body F18-FDG PET-CT
will be performed either at CRE-I (for the clinically noncomplete responders) or at CRE-II (for the clinically complete responders at CRE-I). 2. EUS
with FNA of suspected lymph nodes only during CRE-II, not during CRE-I. CRE: clinical response evaluation; CT: computed tomography; EUS:
endoscopic ultrasonography; FNA: fine-needle aspiration; nCRT: neoadjuvant chemoradiotherapy; EGD: esophagogastroduodenoscopy; PET:
positron-emission tomography; US: ultrasonography.
Study Algorithm
Overview
All included patients will receive nCRT according to the CROSS
protocol (carboplatin, paclitaxel, and concurrent radiotherapy)
[18]. Patients will be reevaluated either once or twice before
undergoing surgical resection during clinical response
evaluations (CRE). The aim of these CREs will be to identify
those patients in whom residual and/or disseminated disease is
present.
CRE-I
The first CRE (CRE-I) will be performed 4-6 weeks after
completion of chemoradiotherapy (Figure 1). During CRE-I,
all patients will undergo esophagogastroduodenoscopy (EGD)
with registration of endoscopic images for future reference and
biopsies of any suspected lesions, including mucosal biopsies
at the site of the primary tumor (1 regular biopsy per centimeter
in each of the 4 quadrants), radial endoscopic ultrasonography
(EUS) for measurement of maximal tumor thickness and area,
and linear EUS. Patients with histological evidence of
locoregional residual disease, but without evidence of
disseminated disease, will be offered immediate surgical
resection. These patients have no clear benefit from
postponement of surgical resection and should therefore have
no delay according to current recommendations. Patients without
histological evidence of locoregional residual disease and
without disseminated disease will be considered to be clinically
complete responders and will be offered a postponed surgical
resection. In these patients a surgical resection will be postponed
for an additional 6-8 weeks, allowing patients more time to
reach a better condition for surgery.
CRE-II
In the week preceding the planned postponed surgical resection,
a second clinical response evaluation (CRE-II) will be
scheduled. CRE-II will be performed only in patients who were
considered to be clinically complete responders (ie, no viable
tumor found) at CRE-I. CRE-II will consist of a PET-CT
(standard for all patients at CRE-II and only for tumor-positive
patients at CRE-I), an EGD with registration of endoscopic
images for future reference, and biopsies of any suspected
lesions, including (random) mucosal biopsies at the site of the
primary tumor, radial EUS for measurement of maximal tumor
thickness and area, and linear EUS plus fine-needle aspiration
(FNA) of PET-positive lesions and/or suspected lymph nodes.
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An important difference between CRE-I and CRE-II will be
that during CRE-I clinically complete responders will be offered
a postponed surgical resection, whereas after CRE-II both
locoregionally complete and noncomplete responders will be
advised to undergo a surgical resection (Figure 1). In other
words, all patients who are considered clinically complete
responders at CRE-I and are therefore allowed to postpone their
surgery by an additional 6-8 weeks, will undergo CRE-II
followed by the postponed surgical resection, irrespective of
the locoregional findings during CRE-II. The diagnostic results
from CRE-II will later be compared with results from both
CRE-I and the final pathological analysis of the resection
specimen. However, patients with (cyto)histological evidence
of disseminated disease during CRE-I or CRE-II will be
excluded from further curative therapy and will be referred for
palliative care.
If after CRE-II the planned operation is postponed for more
than 4 weeks (eg, because the patient has not yet sufficiently
recovered from the nCRT), a CRE-III (comparable to CRE-II)
will be performed 1 week before the (further) postponed
operation.
Surgery
Surgical resection will be attempted immediately after CRE-I
only in those patients who present at CRE-I with histologically
proven residual disease after completion of nCRT, without any
signs of disseminated disease. All other patients will undergo
surgical resection after CRE-II in the absence of distant
metastases.
A transthoracic esophageal resection or a transhiatal approach
can be performed, depending on both patient characteristics and
local expertise and preference. Both open and minimally
invasive techniques are allowed.
A wide local excision including the regional lymph nodes is
carried out in both techniques, including a standard dissection
of the lymph nodes around the coeliac axis. The continuity of
the digestive tract will preferably be restored by a gastric tube
reconstruction or, if required, by a colonic interposition.
At least 15—but preferably 23 or more—lymph nodes should
be aimed to be removed in every patient since it has been shown
that long-term survival is maximized with the removal of at
least 23 nodes [21]. Moreover, the risk of understaging the
tumor in these patients should be minimized. If an insufficient
number of nodes is removed, the patient might be erroneously
staged as ypN0, while in fact ypNpos nodes have been left in
situ (stage migration).
Pathology
All resection specimens will be revised centrally by 2
independent expert pathologists, using a standard protocol. In
case of a discordant outcome, the specimens will be reviewed
by a third independent expert pathologist. A final diagnosis will
be made only if at least 2 pathologists agree. Also, all the CRE-II
biopsies of patients who were considered negative at CRE-II,
but who had more than 10% residual tumor in their resection
specimen will be revised centrally following the same strategy.
In these specimens special attention will be given to the effects
of the preoperative chemoradiation (ie, tumor reduction and
therapy effects). The lymph node dissection should contain at
least 15—but preferably 23 or more—nodes derived from both
mediastinum and upper abdomen, which are essential for correct
ypTNM staging. The resection margins, especially the
circumferential margin, will be evaluated with a 1 mm cutoff
point for vital tumor. This implies that the tumor-free margin
should be larger than 1 mm in order to be classified as R0. If
vital tumor is present at 1 mm or less from the surgical resection
margin, it is considered microscopically positive (R1).
Interim Analysis
An interim analysis will be performed by an independent safety
committee after a total inclusion of 60 patients in order to
carefully monitor serious complications during CRE-I and
CRE-II and to assess the achieved radicality of the performed
operations.
Main Study Parameter/Endpoint
The main study parameter in this study is the correlation
between the clinical response assessment during CRE-I and
CRE-II and the final pathological response in the resection
specimen as measured by the modified tumor regression grading
(TRG) system of Chirieac [22]: no residual carcinoma (TRG1),
1%-10% residual carcinoma (TRG2), 11%-50% residual
carcinoma (TRG3), 51%-100% residual carcinoma (TRG4)
[22].
We propose that in this study TRG2 residual tumors may be
missed as long as we expect them to be detectable reliably as
soon as they have outgrown from TRG2 to TRG3-4 during
follow-up. The risk that TRG2 residual tumors will lead to
irresectability in the short-term is likely to be small/negligible.
However, we do propose that TRG3 and TRG4 residual tumors
should be detected without further delay in order to prevent
short-term loss of resectability and to minimize the risk of
long-term distant disease dissemination. The validity of these
assumptions can only be determined in a future SANO trial, in
which an active surveillance strategy will be compared with
standard surgery in all patients after nCRT.
Statistical Analysis
Sample Size Calculation
As was seen in the previous CROSS trial approximately 40%
of the included patients will have TRG3 or TRG4 residual tumor
in the resection specimen [18]. With a total inclusion of 120
patients, approximately 45 patients will have TRG3 or TRG4
residual tumor. We consider 45 patients a sufficiently large
sample for determining the accuracy of individual and/or
combined diagnostic tests. In order to estimate the distribution
of 120 patients planned to be included, data were used from the
CROSS trial as indicated in Figure 2. Furthermore, several
assumptions were made:
• We assume that during CRE-I clinically complete
responders will comprise patients with TRG1 or TRG2 (as
taken from the pathological response data of the CROSS
trial), whereas clinically noncomplete responders will be
patients with TRG3 or TRG4.
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• The percentage of patients with SCC and AC with TRG1
or TRG2 in the CROSS trial was 78% and 57%,
respectively. This means that approximately 60% of
included patients are expected to have negative
(cyto)histology at CRE-I.
• In a trial by Blom et al [23], approximately 10% of patients
who were reevaluated by PET-CT after completion of nCRT
had newly discovered disseminated disease. We assume
that there will be fewer newly found disseminated disease
with positive (cyto)histology at CRE-II because a number
of these patients are expected to be discovered during
CRE-I.
• We assume that approximately 25% of clinically complete
responders will refuse to undergo the postponed resection
and choose to undergo an active surveillance strategy if no
alarming results are found during CRE-II.
These calculations indicate that approximately 60 patients will
show a clinically complete response after combined diagnostic
investigations during CRE-I and CRE-II (including EUS-FNA
with tumor thickness measurements and PET-CT). Of these,
approximately 15 patients will refuse to undergo surgery and
will undergo active surveillance and approximately 30 patients
will have a pCR (TRG1). The 15 remaining patients are expected
to have residual disease, of whom approximately 12 patients
will have TRG2 residual tumor and approximately 3 patients
will have TRG3 or TRG4 residual tumor. As we proposed
above, TRG2 residual tumors may be missed. Therefore, we
expect that approximately 3 patients with clinically relevant
residual disease (TRG3 or TRG4) will be missed.
In case of unexpected aberrant distribution of patients in the
preSANO trial that leads to decreased TRG3 and TRG4 rates,
results of the first 120 patients will be analyzed following the
present protocol. If these results are promising but do not reach
statistical significance, possibly due to a lack of power, inclusion
of extra patients will be considered. If inclusion of extra patients
is desirable, the protocol will be amended and assessed by the
medical ethics committee.
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Figure 2. Expected distribution of patients (based partly on CROSS trial data). All numbers are based on an inclusion of 120 patients. CI: confidence
interval; CRE: clinical response evaluation; nCRT: neoadjuvant chemoradiotherapy; N: number of patients; TRG: tumor regression grade, as measured
by the modified TRG system of Chirieac. Of the 45 patients who will undergo a postponed resection following CRE-II, 15 patients are expected to have
a pathologically incomplete response (at least TRG2).
Data Analysis
The clinical response evaluation will consist of different
diagnostic modalities. Results of each diagnostic modality will
be presented as categorical or continuous data, depending on
the outcome measure of each diagnostic modality. These results
will be correlated to the (categorical) tumor regression grading
in the resection specimen using a Chi-square-based test
(categorical-categorical) or a 1-way ANOVA test
(continuous-categorical) with post-hoc testing.
Results
The first patient was enrolled on July 23, 2013, and results are
expected in January 2016.
Discussion
The uniqueness of this study lies in the prospective evaluation
of a sufficiently large number of patients, using multiple
diagnostic modalities on different time points. Although
(cyto)histological assessment of biopsies and/or FNAs is the
most objective parameter, several studies have shown that the
response to nCRT is reflected by tumor size or volume as
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assessed by EUS [24-27]. The rationale to include a second
clinical response evaluation before a planned surgical resection
is to allow for a comparison between multiple measurements
and to increase the chance of detecting residual and/or
disseminated disease. It is expected that during CRE-II (due to
an extended time period from the end of nCRT) the F18-FDG
PET-CT signal will have a more favorable signal-to-noise ratio
than has been described previously [28-33] because after 12
weeks the artefacts due to radiation-induced inflammation are
expected to have largely dissolved. This allows for identification
of suspected lymph nodes to be targeted by FNA during CRE-II.
The reason to include patients with SCC as well as patients with
AC in the preSANO trial is that the CROSS regimen has been
shown to be effective in both groups of patients. The pCR rates
of 49% in patients with SCC and 23% in patients with AC in
the CROSS trial provide a rationale for a SANO approach in
both histological subtypes. Furthermore, together with the low
frequency of toxic effects of the CROSS regimen (91% received
the full treatment regimen of nCRT), these high pCR rates
advocate the use of the relatively low dose of 41.4 Gy
radiotherapy [18].
Although we have not yet clearly shown that we are able to
detect a clinically threatening residual cancer 4-6 weeks after
nCRT, there are several arguments why it is not deemed
necessary to do so before we delay the planned surgical resection
with an additional 6-8 weeks. Recently, it was shown that
prolonged time to surgery after nCRT up to at least 12 weeks
had no effect on disease-free and overall survival (HR=1.00
and HR=1.06 per additional week, P=.976 and P=.139,
respectively). Moreover, prolonged time to surgery increased
the probability of pCR in the resection specimen (odds ratio =
1.35 per additional week of time to surgery, P=.0004) [34].
Comparable results have been published by other groups [35,36].
Postoperative mortality and severe morbidity (grade ≥3
according to the Clavien-Dindo classification [20]) after
esophagectomy in the Netherlands is 5% and 60%, respectively.
Thus, a nonsurgical treatment strategy in patients with a
clinically complete response after nCRT theoretically saves up
to 5% mortality and 60% severe morbidity in this patient group.
Moreover, this approach might improve quality of life and might
lead to a reduction in health care costs. Therefore, we will
consider this study as successful when the results of the
combined diagnostic modalities lead to a maximum percentage
of clinically false-negative TRG3 and TRG4 tumors of twice
the postoperative mortality (ie, 10%). If more than 10% of TRG3
or TRG4 tumors are missed, the SANO trial will be
reconsidered.
If the preSANO trial shows that TRG3 and TRG4 residual tumor
can be predicted reliably, a randomized trial comparing nCRT
plus standard surgery versus chemoradiotherapy plus surgery
as needed in oesophageal cancer patients (the SANO trial) will
be conducted. Hopefully, this SANO trial will result in an
organ-preserving treatment strategy for a selected group of
patients and therefore reduce treatment related morbidity and
mortality, improve quality of life, and lead to a reduction in
health care costs.
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